Sunghee Park

Sunghee Park

Auto-generated profile, based on publicly available information

Sunghee Park

Division of Infectious Diseases, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Korea

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
HCHyemin Chung
Hyemin Chung
HSHyeonji Seo
Hyeonji Seo
SPSunghee Park
Sunghee Park
HKHaein Kim
Haein Kim
JJJiwon Jung
Jiwon Jung
MKMin Jae Kim
Min Jae Kim
Chung H, et al. J Korean Med Sci. 2021 Jun;36(25):e181. https://doi.org/10.3346/jkms.2021.36.e181

1 January 2025 in Infection & Chemotherapy
Verified
Journal Article
Open access
TKTark Kim
Tark Kim
YHYoon-Kyoung Hong
Yoon-Kyoung Hong
SPSunghee Park
Sunghee Park
JJJongtak Jung
Jongtak Jung
OCOh-Hyun Cho
Oh-Hyun Cho
YCYong Pil Chong
Yong Pil Chong
Owing to concern that carbapenemase-producing strains among carbapenem-resistant Pseudomonas aeruginosa (CRPA) isolates is on the rise, we investigated the genetic epidemiology and antimicrobial susceptibilities of clinical CRPA isolates collected in four academic hospitals in Korea. Carbapenemase genes were detected in 46 of 63 CRPA isolates (73.0%) collected between 2021 and 2024, and blaNDM ST773 was the most common genotype (27 isolates, 42.9%), followed by blaNDM ST644 (9 isolates, 14.3%) and blaIMP ST235 (7 isolates, 11.1%). Overall susceptibility to ceftazidime/avibactam was only 17.5%, and none of the carbapenemase-producing isolates were susceptible to it. All ST644 strains were also resistant to aztreonam.

1 January 2022 in Infection & Chemotherapy
Verified
Journal Article
Open access
PDF file
SPSunghee Park
Sunghee Park
SPSe Yoon Park
Se Yoon Park
ELEunjung Lee
Eunjung Lee
TKTae Hyong Kim
Tae Hyong Kim
ELEunyoung Lee
Eunyoung Lee
Park S, et al. Infect Chemother. 2022 Jun;54(2):308-315. https://doi.org/10.3947/ic.2022.0033

4 October 2023 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Open access
PDF file
SPSe Yoon Park
Se Yoon Park
JKJaewoong Kim
Jaewoong Kim
ELEunjung Lee
Eunjung Lee
SPSunghee Park
Sunghee Park
JPJung-Wan Park
Jung-Wan Park
TKTae Hyong Kim
Tae Hyong Kim
Objective: We investigated gender differences in psychosocial determinants that affect hand hygiene (HH) performance among physicians.Design: The survey included a structured questionnaire with 7 parts: self-assessment of HH execution rate; knowledge, attitude, and behavior regarding HH; internal and emotional motivation for better HH; barriers to HH; need for external reminders; preference for alcohol gel; and embarrassment due to supervision.Setting: The study was conducted across 4 academic referral hospitals in Korea.Participants: Physicians who worked at these hospitals were surveyed.Methods: The survey questionnaire was sent to 994 physicians of the hospitals in July 2018 via email or paper. Differences in psychosocial determinants of HH among physicians were analyzed by gender using an independent t test or the Fisher exact test.Results: Of the 994 physicians, 201 (20.2%) responded to the survey. Among them, 129 (63.5%) were men. Male physicians identified 4 barriers as significant: time wasted on HH (P = .034); HH is not a habit (P = .004); often forgetting about HH situations (P = .002); and no disadvantage when I do not perform HH (P = .005). Female physicians identified pain and dryness of the hands as a significant obstacle (P = .010), and they had a higher tendency to feel uncomfortable when a fellow employee performed inadequate HH (P = .098). Among the respondents, 26.6% identified diversifying the types of hand sanitizers as their first choice for overcoming barriers to improving HH, followed by providing reminders (15.6%) and soap and paper towels in each hospital room (13.0%).Conclusion: A significant difference in the barriers to HH existed between male and female physicians. Promoting HH activities could help increase HH compliance.

23 October 2023 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Closed access
PDF file
SPSunghee Park
Sunghee Park
SLSeung Hyun Lee
Seung Hyun Lee
HJHye Jung Jung
Hye Jung Jung
JSJi Eun Shin
Ji Eun Shin
JMJi Eun Moon
Ji Eun Moon
TKTark Kim
Tark Kim
In this observational study conducted in 2022, 12.3% of patients who shared a room with a patient positive for severe acute respiratory coronavirus virus 2 (SARS-CoV-2) also had a positive polymerase chain reaction (PCR) test, either at initial screening or during a 5-day quarantine. Therefore, screening and quarantine are still necessary within hospitals for close-contact inpatients during the SARS-CoV-2 omicron-variant dominant period.

31 March 2026 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
GLGyeongmin Lim
Gyeongmin Lim
JSJu-Young Shin
Ju-Young Shin
DHDa Eun Hyeon
Da Eun Hyeon
JKJi Hyun Kim
Ji Hyun Kim
YKYuna Kim
Yuna Kim
JKJu Hwan Kim
Ju Hwan Kim
INTRODUCTION: Proton pump inhibitors (PPIs) have been associated with an increased risk of Clostridioides difficile infection (CDI) in previous observational studies. However, real-world evidence on the CDI risk of potassium-competitive acid blockers (P-CABs), a newer class of acid suppressive agents, remains limited. METHODS: We conducted a retrospective cohort study using electronic health record data from 15 hospitals standardized to the Observational Medical Outcomes Partnership Common Data Model and integrated through Federated E-Health Big Data for Evidence Renovation Network. Patients newly prescribed P-CABs, proton pump inhibitors (PPIs), or histamine 2 receptor antagonists (H2RAs) were included and the primary outcome was the occurrence of CDI. After 1:4 propensity score matching, pairwise comparisons were conducted using Cox proportional hazards models. Hazard ratios (HRs) and 95% confidence intervals (CIs) were then pooled across databases by meta-analysis. RESULTS: In the 1:4 matched cohorts, we identified 61,596 P-CAB users (mean follow-up, 72.6 ± 29.9 days) and 132,683 PPI users (74.9 ± 28.6 days), 42,794 P-CAB users (69.5 ± 32.4 days) and 89,415 H2RA users (69.9 ± 33.1 days), and 85,686 PPI users (71.1 ± 31.2 days) and 159,178 H2RA users (68.0 ± 33.8 days) across the 3 pairwise comparisons. The pooled HRs were 0.87 (95% CI, 0.69–1.10) for P-CABs vs PPIs, 0.85 (0.64–1.12) for P-CABs vs H2RAs, and 1.13 (0.98–1.29) for PPIs vs H2RAs. Results were generally consistent across subgroup and sensitivity analyses. DISCUSSION: In this cohort study, P-CAB use was not associated with a higher risk of CDI compared with PPIs or H2RAs.